Testagen

Testagen is marketed for reproductive and testicular support based on its name, but the actual peptide (Lys-Glu-Asp-Gly) was built from the amino-acid makeup of pituitary-gland extracts, and the published animal research on it covers the thyroid and thymus, not the testes. It's from the Russian 'Khavinson' bioregulator family. It is not an FDA-approved drug, and the evidence comes only from cells and birds, not humans.

Testagen is marketed for reproductive and testicular support, but the research does not show that. Lab work confirmed its sequence and showed it can enter a cell's nucleus and bind DNA in a sequence-preferential way, and animal work in birds whose pituitary had been removed reported recovery of thyroid and thymus structure and higher thyroid hormone — but no published study shows an effect on testicular or reproductive tissue; that connection is an assumption, not a finding. There are no large controlled human trials.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen"). Despite the name, the reproductive/testicular association is not supported by the primary literature: Lys-Glu-Asp-Gly was synthesized from the amino-acid composition of anterior-pituitary extracts, and its documented preclinical effects are on thyroid structure/hormones and thymus morphology in hypophysectomized birds. Any testosterone or reproductive angle is an indirect, unproven extrapolation. Evidence is almost entirely preclinical (cell/DNA-binding plus bird studies); no large controlled human trials. WADA: not specifically named; best treated as S0 (non-approved), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled. Not eligible for 503A pharmacy compounding.

Testagen has essentially no controlled human safety data and is not FDA-approved. It is not a treatment for any reproductive, fertility, or thyroid condition — those warrant a clinician. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. Testagen is not FDA-approved and is not a treatment for fertility, testosterone, or any reproductive condition. Its evidence is preclinical. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Testagen is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology, sharing a thin, mostly-preclinical, largely single-institute evidence base and no large controlled human trials.[²]

⚠️ Name caution — and a tissue-label correction. Despite the name, Testagen is not testosterone and is not a hormone; it is a four-amino-acid peptide, and it does not replace hormone evaluation or therapy. More importantly, the "reproductive/testicular" tissue label that follows from the name is not what the primary literature shows. Lys-Glu-Asp-Gly was synthesized from the amino-acid composition of anterior-pituitary extracts, and the preclinical studies on it report effects on thyroid structure and thyroid hormone levels, and on thymus morphology, in hypophysectomized birds.[³][⁴][⁵] No published study reports an effect on testicular or reproductive tissue. Vendor pages that market it for men's health reach that claim through an indirect and unproven thyroid-to-testosterone rationale — treat it as marketing, not evidence.

Testagen is a synthetic tetrapeptide, Lys-Glu-Asp-Gly (KEDG), in the "Khavinson" bioregulator family (note: it is not a hormone or testosterone). According to PubMed, a molecular study confirmed Testagen's sequence and showed that, like Epithalon and Pinealon, it can penetrate a cell's nucleus and bind DNA in a sequence-preferential way (preferring certain motifs such as CAG-containing sequences), supporting the group's idea that short peptides can epigenetically influence gene activity.[¹]

The tissue association: pituitary/thyroid/thymus, not testis. The Kuznik/Pateyuk group at Chita State Medical Academy synthesized Lys-Glu-Asp-Gly from the amino-acid composition of anterior-pituitary extracts and studied it repeatedly in hypophysectomized birds. In those studies the peptide was associated with normalization of thyroid structure and of thyrotropic and thyroid hormone levels,[³][⁵] and with recovery of thymus morphology — where the abstract calls Lys-Glu-Asp-Gly the "anterior pituitary peptide."[⁴] The papers describe these tetrapeptides as built from the amino-acid composition of pituitary cytomedins.[⁵]

No study reports a testicular or reproductive effect. The reproductive framing appears to come from the name and from vendor pages, which themselves describe the men's-health angle as flowing *indirectly* from TSH and thyroid function to downstream testosterone regulation — an extrapolation, not a measured result. The Khavinson 2002 umbrella review [²] is sometimes cited for the tissue association, but it does not mention Testagen and does not establish one; it supports only the generic "short peptides can influence gene activity" framing.

Evidence quality. Preclinical — cell/DNA-binding work plus bird studies from a single research group. No large controlled human trials. See the shared Khavinson caveat below.

### About the Khavinson bioregulators (shared framing)

Developed from the 1970s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, these cytomedin/cytogen peptides went from organ-extract complexes to synthetic short peptides proposed to have tissue-specific effects under a "peptide theory of ageing."[²] Honest caveats: evidence is overwhelmingly preclinical plus small, often non-blinded Russian studies; no large independent randomized trials; none FDA-approved; sold in Russia as injectables and supplements.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled. Not eligible for 503A pharmacy compounding — not on the FDA 503A bulks list, no USP/NF monograph, and not a component of an FDA-approved drug.

Regulatory status (sport — WADA). Not specifically named; best treated as S0 (non-approved), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Reproductive/men's-health support — the dominant marketed use, and the one with no supporting study. The preclinical interest that does exist is in thyroid and thymus/immune endpoints in birds, which is not an established human use either.

Commonly reported

• Injection-site reactions
• Reactions to research-supply material of variable purity
• DNA-interacting activity. Testagen binds DNA sequence-preferentially in vitro;[¹] long-term consequences in humans are uncharacterized.
• Unknown long-term safety.

Not a treatment for fertility, low testosterone, or any reproductive condition — see a clinician; it is not a hormone

Pregnancy and lactation — not applicable/no data

Pediatric use — no data; not for researchers under 18

Active malignancy — caution; effects of gene-activity-modulating peptides in the cancer context are uncharacterized

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0. Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each marketed as linked to one tissue. The marketed tissue and the researched tissue do not always match — for this one they do not.

Hypophysectomized

An animal whose pituitary gland has been surgically removed. This is the model the Testagen animal studies used.

Sequence-specific DNA binding

Binding preferentially to particular DNA motifs. Testagen showed this in the lab, proposed as a way it could influence gene activity.

Cell-nucleus penetration

Getting into the nucleus, where DNA lives. Testagen was shown to do this in cultured cells.

Preclinical

Research in cells or animals, before human testing.

1. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11):1210–1219.(PMID 22117547)
2. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)
3. Kuznik BI, Pateyuk AV, Rusaeva NS, Baranchugova LM, Obydenko VI. (2011). Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens. Bulletin of Experimental Biology and Medicine, 150(4):495–9.(PMID 22268052)
4. Pateyk AV, Baranchugova LM, Rusaeva NS, Obydenko VI, Kuznik BI. (2013). Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of Experimental Biology and Medicine, 154(5):681–5.(PMID 23658898)
5. Kuznik BI, Pateyuk AV, Rusaeva NS. (2008). Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens. Bulletin of Experimental Biology and Medicine, 145(1):104–7.(PMID 19024016)

• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class
• Crystagen — same mechanism class